Everstar Asset Management LLC Sells 4,531 Shares of GSK plc (NYSE:GSK)

Everstar Asset Management LLC lessened its stake in shares of GSK plc (NYSE:GSK) by 36.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 7,963 shares of the pharmaceutical company’s stock after selling 4,531 shares during the quarter. Everstar Asset Management LLC’s holdings in GSK were worth $269,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Dorsey & Whitney Trust CO LLC lifted its position in GSK by 2.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock worth $389,000 after acquiring an additional 278 shares during the last quarter. Sunbelt Securities Inc. grew its stake in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares in the last quarter. Rehmann Capital Advisory Group boosted its position in shares of GSK by 6.3% during the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after acquiring an additional 332 shares in the last quarter. GC Wealth Management RIA LLC increased its stake in shares of GSK by 2.6% in the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock valued at $474,000 after purchasing an additional 353 shares during the last quarter. Finally, Jacobi Capital Management LLC grew its position in GSK by 3.9% in the fourth quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company’s stock valued at $352,000 after acquiring an additional 389 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Trading Up 0.2 %

Shares of GSK stock opened at $38.81 on Tuesday. The stock has a market capitalization of $80.33 billion, a PE ratio of 24.41, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.93. The stock has a 50 day moving average price of $37.33 and a two-hundred day moving average price of $36.66. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, equities analysts anticipate that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a $0.3932 dividend. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. This represents a $1.57 annualized dividend and a yield of 4.05%. GSK’s dividend payout ratio (DPR) is presently 98.74%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on GSK shares. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley started coverage on shares of GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.